Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

3.905 -0.025 (-0.64%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
US Stocks Edge Higher; D.R. Horton Posts Upbeat Earnings
Via Benzinga
Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer
From Agenus Inc.
Via Business Wire
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
From Agenus Inc.
Via Business Wire
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
From Agenus Inc.
Via Business Wire
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
This small-cap biotech stock is surging. Time to buy? 
Via The Motley Fool
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
From Agenus Inc.
Via Business Wire
Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
From Agenus
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Agenus Announces Virtual Annual Shareholders Meeting
From Agenus Inc.
Via Business Wire
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
Though risky, investors who buy biotech stocks watch their portfolios skyrocket when their drugs work as intended. 
Via InvestorPlace
7 Biotech Stocks to Put on Your Breakthrough Radar
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Agenus Inc.
Via Business Wire
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
From Agenus Inc.
Via Business Wire
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
From Agenus Inc.
Via Business Wire
3 Magnificent Growth Stocks to Buy Hand Over Fist
Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst. 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
From Agenus Inc.
Via Business Wire
Agenus (AGEN) Q1 2024 Earnings Call Transcript
AGEN earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
AGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q1 2024
AGEN stock results show that Agenus missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Agenus Reports First Quarter 2024 Results
From Agenus Inc.
Via Business Wire
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Agenus Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
From Agenus Inc.
Via Business Wire
Top 2 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
From Agenus Inc.
Via Business Wire
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings. 
Via Benzinga
Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom
The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity. 
Via Benzinga
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
From Agenus Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.